Early Use of Mepolizumab Helps a Heart Attack Patient with Rare Allergy‑Related Disease

A patient who had severe heart attacks caused by a rare allergic inflammation called eosinophilic granulomatosis with polyangiitis (EGPA) was treated early with the drug mepolizumab. The condition, which involves high levels of a white‑blood‑cell type called eosinophils, can attack the blood vessels that supply the heart. When the patient’s heart spasms did not respond to standard medications, doctors tried mepolizumab soon after the diagnosis of EGPA was confirmed. The drug blocks a protein that feeds eosinophils, reducing the inflammation inside the coronary arteries.

Within weeks of starting treatment, the patient’s heart spasms stopped and the severe chest pain that had led to several hospitalizations disappeared. Follow‑up scans showed a clear improvement in blood flow and no new heart attacks occurred during the next year. This case suggests that using mepolizumab early, rather than waiting for multiple heart attacks, may protect patients with EGPA from life‑threatening heart problems. It also highlights the importance of recognizing rare allergic diseases as a possible cause when patients have unexplained heart spasms or attacks.

Actions